Wockhardt has received approval for two new antibiotics, Emrok(IV) &Emrok O, which are used for acute bacterial skin and skin structure infections including diabetic foot infections and concurrent bacteraemia.This approval by the Indian drug regulator DCGI is claimed to be the country's first new discovery antibiotics.

Wockhardt said the two approved new antibiotics, Emrok(IV) & Emrok O are used for acute bacterial skin and skin structure infections including diabetic foot infections and concurrent bacteraemia. The new drug will target superbug like Methicillin-resistant Staphylococcus aureus (MRSA), which is a leading cause of rising antimicrobial resistance (AMR).

Dr.Habil Khorakiwala, Founder Chairman,Wockhardt Group said, “I believe EMROK/EMROK-Ohas a strong potential to effectively address the unmet medical need of the clinicians in the country thereby helping to reduce the morbidity and mortality.”

This approval by the Indian drug regulator DCGIis claimed to be the country's first new discovery antibiotics.